HLA-DR1, -DR5, and -DR8 antigen disparities are associated with acute steroid-resistant rejection and poor kidney graft survival.
Salmela
K
K
4th Department of Surgery, Helsinki University Central Hospital, Finland.
von Willebrand
E
E
Kyllönen
L
L
Koskimies
S
S
Isoniemi
H
H
Eklund
B
B
Höckerstedt
K
K
Ahonen
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival; D006684:HLA-DR Antigens / Q000276:immunology*; D059810:HLA-DR Serological Subtypes; D015798:HLA-DR1 Antigen / Q000276:immunology*; D015805:HLA-DR5 Antigen / Q000276:immunology*; D006648:Histocompatibility; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3; D010956:Plasmapheresis; D013997:Time Factors; D014019:Tissue Donors
D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; D015798:HLA-DR1 Antigen; D015805:HLA-DR5 Antigen; C041559:HLA-DR8 antigen; D016853:Muromonab-CD3; D008775:Methylprednisolone